DUAL GIP-GLP-1 RECEPTOR AGONIST TIRZEPATIDE IMPROVES GLUCOSE CONTROL AND INSULIN SENSITIVITY IN MIXED MEAL TESTS IN PEOPLE WITH TYPE 2 DIABETES

Background and aim Tirzepatide, a dual GIP and GLP-1 receptor agonist, produced superior glycemic control and body weight reductions as compared with selective GLP-1 receptor agonists in type 2 diabetes (T2D) clinical trials. We explored the effects of tirzepatide on glucose control and on measures of insulin sensitivity during standardized mixed-meal tolerance testing (sMMTT).